U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT07532148) titled 'Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer' on April 09.
Brief Summary: Clinical Trial to evaluate the pharmacokinetic Characteristics, safety and Tolerability among CKD-215 and D215
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
Ovarian Cancer
Intervention:
DRUG: CKD-215
2 tablets BID at 12-hour intervals for 7 days
DRUG: D215
2 tablets BID at 12-hour intervals for 7 days
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Chong Kun Dang Pharmaceutical
Published by HT Digital Content Services with permission from Health Daily Dige...